Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 8 | 2023 | 601 | 1.740 |
Why?
|
| Vulvar Neoplasms | 4 | 2024 | 58 | 1.630 |
Why?
|
| Carcinoma, Squamous Cell | 6 | 2024 | 330 | 1.560 |
Why?
|
| Cytodiagnosis | 3 | 2024 | 42 | 1.240 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2024 | 60 | 1.080 |
Why?
|
| Immunohistochemistry | 6 | 2024 | 973 | 0.990 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2024 | 214 | 0.970 |
Why?
|
| Observer Variation | 2 | 2024 | 136 | 0.960 |
Why?
|
| Competency-Based Education | 1 | 2024 | 28 | 0.940 |
Why?
|
| Carcinoma | 2 | 2023 | 139 | 0.910 |
Why?
|
| Carcinoma in Situ | 2 | 2015 | 73 | 0.910 |
Why?
|
| Endometrial Neoplasms | 2 | 2015 | 137 | 0.870 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 118 | 0.860 |
Why?
|
| Lymphoma | 1 | 2023 | 65 | 0.850 |
Why?
|
| Clinical Competence | 1 | 2024 | 397 | 0.760 |
Why?
|
| Gynecology | 1 | 2020 | 49 | 0.690 |
Why?
|
| Endosonography | 2 | 2023 | 94 | 0.680 |
Why?
|
| Dermatology | 1 | 2020 | 52 | 0.670 |
Why?
|
| Skin Diseases | 1 | 2020 | 114 | 0.670 |
Why?
|
| Peripheral Nerves | 2 | 2015 | 48 | 0.610 |
Why?
|
| Endometrial Hyperplasia | 2 | 2015 | 14 | 0.590 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2024 | 108 | 0.590 |
Why?
|
| Middle Aged | 19 | 2024 | 12356 | 0.580 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 34 | 0.560 |
Why?
|
| Lymph Nodes | 2 | 2017 | 258 | 0.550 |
Why?
|
| Inflammation | 1 | 2020 | 608 | 0.530 |
Why?
|
| Breast Neoplasms | 2 | 2023 | 1187 | 0.530 |
Why?
|
| Epithelioid Cells | 1 | 2015 | 13 | 0.520 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2015 | 22 | 0.510 |
Why?
|
| Humans | 35 | 2024 | 50201 | 0.500 |
Why?
|
| Fibroma | 1 | 2015 | 39 | 0.500 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 487 | 0.490 |
Why?
|
| Stromal Cells | 1 | 2015 | 72 | 0.490 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 56 | 0.490 |
Why?
|
| Classification | 1 | 2015 | 14 | 0.480 |
Why?
|
| PAX2 Transcription Factor | 1 | 2015 | 22 | 0.480 |
Why?
|
| World Health Organization | 1 | 2015 | 49 | 0.480 |
Why?
|
| Female | 24 | 2024 | 26829 | 0.460 |
Why?
|
| Neoplasms | 1 | 2024 | 1233 | 0.450 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2023 | 46 | 0.440 |
Why?
|
| Blood Component Removal | 1 | 2012 | 10 | 0.400 |
Why?
|
| Blood Banks | 1 | 2012 | 18 | 0.400 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 3158 | 0.390 |
Why?
|
| Blood Transfusion | 1 | 2012 | 127 | 0.370 |
Why?
|
| Retrospective Studies | 6 | 2023 | 6190 | 0.360 |
Why?
|
| Aged | 9 | 2024 | 9505 | 0.360 |
Why?
|
| Lipoma | 1 | 2009 | 18 | 0.340 |
Why?
|
| Adult | 14 | 2023 | 13486 | 0.330 |
Why?
|
| Corpus Callosum | 1 | 2009 | 29 | 0.330 |
Why?
|
| Cerebral Palsy | 1 | 2009 | 39 | 0.330 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 402 | 0.320 |
Why?
|
| Young Adult | 6 | 2023 | 4052 | 0.320 |
Why?
|
| Biopsy | 4 | 2020 | 592 | 0.310 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 226 | 0.300 |
Why?
|
| Seizures | 1 | 2009 | 195 | 0.290 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2020 | 49 | 0.290 |
Why?
|
| Papillomavirus Infections | 3 | 2024 | 167 | 0.270 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 286 | 0.260 |
Why?
|
| Neoplasm, Residual | 2 | 2018 | 160 | 0.250 |
Why?
|
| Cytological Techniques | 1 | 2024 | 14 | 0.230 |
Why?
|
| Pathology | 1 | 2024 | 38 | 0.230 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 1041 | 0.230 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 88 | 0.220 |
Why?
|
| Predictive Value of Tests | 2 | 2024 | 921 | 0.220 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 1195 | 0.210 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2022 | 5 | 0.200 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 213 | 0.200 |
Why?
|
| Dizziness | 1 | 2022 | 13 | 0.200 |
Why?
|
| Consensus | 2 | 2020 | 158 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2015 | 277 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 630 | 0.190 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 749 | 0.190 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2020 | 2 | 0.180 |
Why?
|
| Vulva | 1 | 2020 | 17 | 0.180 |
Why?
|
| Research Report | 1 | 2020 | 16 | 0.180 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 269 | 0.180 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2019 | 14 | 0.170 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2019 | 24 | 0.170 |
Why?
|
| Male | 11 | 2023 | 25572 | 0.160 |
Why?
|
| Risk Factors | 4 | 2015 | 3644 | 0.160 |
Why?
|
| Carbachol | 1 | 2018 | 27 | 0.150 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2018 | 17 | 0.150 |
Why?
|
| Picornaviridae Infections | 1 | 2018 | 18 | 0.150 |
Why?
|
| Keratins | 1 | 2017 | 27 | 0.140 |
Why?
|
| Skin | 1 | 2020 | 416 | 0.140 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 146 | 0.140 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2017 | 59 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2015 | 548 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2020 | 2396 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 1 | 2017 | 22 | 0.140 |
Why?
|
| Metabolome | 1 | 2017 | 92 | 0.140 |
Why?
|
| Tracheal Neoplasms | 1 | 2016 | 8 | 0.130 |
Why?
|
| Granular Cell Tumor | 1 | 2016 | 6 | 0.130 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 51 | 0.130 |
Why?
|
| Disease Progression | 2 | 2017 | 821 | 0.130 |
Why?
|
| Logistic Models | 2 | 2015 | 901 | 0.130 |
Why?
|
| Pulmonary Medicine | 1 | 2015 | 15 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2017 | 347 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 123 | 0.120 |
Why?
|
| Colposcopy | 1 | 2015 | 18 | 0.120 |
Why?
|
| Endometrium | 1 | 2015 | 40 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 280 | 0.120 |
Why?
|
| Adolescent | 4 | 2020 | 6459 | 0.120 |
Why?
|
| Adrenal Glands | 1 | 2014 | 40 | 0.120 |
Why?
|
| Hysterectomy | 1 | 2015 | 88 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 83 | 0.120 |
Why?
|
| Taxoids | 1 | 2014 | 37 | 0.110 |
Why?
|
| Urinary Bladder | 1 | 2014 | 93 | 0.110 |
Why?
|
| Lung | 1 | 2018 | 507 | 0.110 |
Why?
|
| Cervix Uteri | 1 | 2014 | 48 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 67 | 0.110 |
Why?
|
| Leiomyoma | 1 | 2013 | 25 | 0.110 |
Why?
|
| Esophageal Diseases | 1 | 2013 | 20 | 0.110 |
Why?
|
| Calcinosis | 1 | 2013 | 52 | 0.110 |
Why?
|
| Patient Selection | 1 | 2015 | 254 | 0.110 |
Why?
|
| Lymphangitis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Prognosis | 2 | 2015 | 1963 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 331 | 0.110 |
Why?
|
| Pruritus | 1 | 2013 | 44 | 0.100 |
Why?
|
| Eosinophilia | 1 | 2013 | 36 | 0.100 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2012 | 5 | 0.100 |
Why?
|
| Edema | 1 | 2013 | 68 | 0.100 |
Why?
|
| Donor Selection | 1 | 2012 | 12 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2013 | 104 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 209 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 281 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5203 | 0.090 |
Why?
|
| Dyspnea | 2 | 2022 | 74 | 0.090 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 2188 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2009 | 97 | 0.080 |
Why?
|
| Time Factors | 1 | 2015 | 2909 | 0.080 |
Why?
|
| Blood Donors | 1 | 2009 | 31 | 0.080 |
Why?
|
| Telemedicine | 1 | 2015 | 467 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 147 | 0.070 |
Why?
|
| Fatal Outcome | 2 | 2019 | 195 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1176 | 0.060 |
Why?
|
| Physicians | 1 | 2009 | 229 | 0.060 |
Why?
|
| United States | 2 | 2015 | 4898 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 871 | 0.050 |
Why?
|
| Lost to Follow-Up | 1 | 2020 | 10 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2020 | 102 | 0.040 |
Why?
|
| Chest Pain | 1 | 2019 | 55 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2017 | 22 | 0.040 |
Why?
|
| Rhinovirus | 1 | 2018 | 22 | 0.040 |
Why?
|
| Kynurenine | 1 | 2017 | 14 | 0.040 |
Why?
|
| Glutathione Disulfide | 1 | 2017 | 40 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 182 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 52 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2016 | 12 | 0.030 |
Why?
|
| Genotype | 1 | 2018 | 542 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 409 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2016 | 46 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 70 | 0.030 |
Why?
|
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 8 | 0.030 |
Why?
|
| Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
|
| Laser Therapy | 1 | 2016 | 84 | 0.030 |
Why?
|
| Cost Savings | 1 | 2015 | 58 | 0.030 |
Why?
|
| S100 Proteins | 1 | 2015 | 34 | 0.030 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2014 | 8 | 0.030 |
Why?
|
| Oncogene Fusion | 1 | 2014 | 4 | 0.030 |
Why?
|
| Carcinoma, Verrucous | 1 | 2014 | 6 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 17 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 270 | 0.030 |
Why?
|
| Curettage | 1 | 2014 | 13 | 0.030 |
Why?
|
| Urothelium | 1 | 2014 | 18 | 0.030 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2014 | 29 | 0.030 |
Why?
|
| Hematuria | 1 | 2014 | 26 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 581 | 0.030 |
Why?
|
| Mitosis | 1 | 2014 | 88 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 288 | 0.030 |
Why?
|
| Skin Tests | 1 | 2013 | 55 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 246 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2013 | 91 | 0.030 |
Why?
|
| Rural Health Services | 1 | 2015 | 168 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 344 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 242 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 584 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 2609 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 321 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1414 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 1160 | 0.020 |
Why?
|
| Liver | 1 | 2017 | 1122 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 1255 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 1529 | 0.020 |
Why?
|
| Virginia | 1 | 2009 | 19 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 665 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 173 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 1288 | 0.020 |
Why?
|
| Self Report | 1 | 2009 | 202 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1580 | 0.010 |
Why?
|